Amgen

1Q Revenues: $3.7 billion (+15%)

1Q Earnings: $1.1 billion (+10%)

Comments: Aranesp sales grew 14% to $1 billion; Enbrel sales (Amgen only) rose 11% to $730 million, Neulasta sales were up 17% to $714 million, while Epogen and Neupogen grew modestly, between 3 and 4% to $625 million and $299 million respectively. New product Vectibix posted $51 million it its first 1Q. Sensipar sales were up 72% to $105 million.